Mixed signals: Biotech executives face conflicting signs on growth


Faced with conflicting signs from all sides of the biotech economy, executives are left sorting out how to plan for growth.

Previous Most Influential Business Women 2022: Carlita Vasser uses years of nursing experience to lead At Home Care
Next FDA gives Durham's BioCryst green light to resume trial enrollment